Feb 28, 2024 · Nivolumab is a monoclonal antibody for managing metastatic melanoma and other malignancies. The drug targets the PD1 receptor, an immune checkpoint, thus embodying a potent form of immunotherapy. This action obstructs the signal that impedes the activation of T-cells against cancerous cells.

Nivolumab's mechanism of action is based on its role as a monoclonal antibody that selectively binds to the programmed death-1 (PD-1) receptor on the surface of T cells, a type of white blood cell that plays a crucial role in the immune system’s ability to combat malignancies.

Nivolumab is a PD-1 blocking antibody used to treat melanoma, non small-cell lung cancer, renal cell cancer, head and neck cancer, and Hodgkin lymphoma. Brand Names Opdivo, Opdivo Qvantig, Opdualag

Nivolumab binds to the PD-1 receptor and blocks its interaction with PD-L1 and PD-L2, thereby relieving T cell exhaustion and improving cytokine production 1. The combination of nivolumab- and relatlimab-mediated inhibition increases T cell activity compared to the activity of either antibody alone 1. Targeting of normal cells can occur.

Explore the mechanism of disease & mechanism of action for OPDIVO® (nivolumab) and OPDIVO® treatment combination therapies. Please see Indications and Important Safety Information.

Nivolumab, a fully human immunoglobulin G4 PD-1 immune checkpoint inhibitor antibody, blocks PD-1 and promotes antitumor immunity, and it is effective for treating non-small-cell lung cancer (NSCLC), melanoma, renal cell carcinoma (RCC) and other cancers.

Nivolumab (Opdivo; Nivolumab BMS) was first PD-1 immune checkpoint inhibitor to be approved for use in advanced, squamous (SQ) nonsmall cell lung cancer (NSCLC) following prior chemotherapy. Nivolumab is a human immunoglobulin G4 (IgG4) monoclonal antibody.

Sep 29, 2023 · Nivolumab is a human immunoglobulin G4 monoclonal antibody that binds to the PD-1 receptor and blocks its interaction with PD-L1 and PD-L2, releasing PD-1 pathway-mediated inhibition of the immune response, including antitumour immune response.

Nivolumab is a human monoclonal antibody to programmed cell death receptor 1 (PD-1), which acts as a checkpoint inhibitor and is used in the immunotherapy of several forms of advanced or metastatic cancer.

Feb 28, 2024 · Nivolumab is a monoclonal antibody for managing metastatic melanoma and other malignancies. The drug targets the PD1 receptor, an immune checkpoint, thus embodying a potent form of immunotherapy. This action obstructs the signal that impedes the activation of T-cells against cancerous cells.